The FDA has doled out its most serious classification to a recall of some Cardinal Health medical supplies.
Lenz Therapeutics is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss and $225 million in cash on hand at close.
Mural Oncology, Alkermes’ cancer spinoff, has officially landed with $275 million in funding and a mission to develop an interleukin-2 (IL-2) candidate for solid tumors.
Just a few months after the official U.S. launch of its Sensora platform, Eko Health has published a study detailing the real-world performance of the platform’s first artificial intelligence-powered heart disease detection tool.
CROs Alimentiv, AcelaBio and PharmaNest are partnering in an effort to leverage precision medicine and AI-backed digital pathology tools to boost clinical trials for nonalcoholic steatohepatitis (NASH).
A small molecule alleviates four different types of acute and chronic pain in rodents, so far with none of the side effects associated with widely prescribed non-opioid painkiller gabapentin.
Lawrence Blatt, Ph.D., CEO of Aligos Therapeutics, knows a thing or two about the slow drip of progress that has defined treating viral liver infections. He was “thrilled” back in the mid-90s when a drug he co-invented at Amgen, Infergen, notched a 10% response rate in patients with hepatitis C. In 1998, ribavirin was approved as a first-line treatment, which, when combined with interferon, roughly tripled response rates.
Ipsen and Genfit have shown off the data they believe can finally secure approval of their liver disease candidate elafibranor. The publication puts meat on the bones of an earlier data drop, providing a closer look at how the therapy holds up against Intercept Pharmaceuticals’ Ocaliva and CymaBay Therapeutics’ own challenger.
England’s NICE recommends hybrid closed-loop systems for Type 1 diabetes, prompting praise from Medtronic, Dexcom
The National Institute for Health and Care Excellence (NICE), England’s cost-effectiveness watchdog, has finalized a draft guidance regarding hybrid closed-loop systems, concluding that the technology should be made broadly affordable and accessible to help people with Type 1 diabetes better manage the condition.
Selecta fuses with Cartesian in reverse merger, bolstering finances for autoimmune cell therapy goals
Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs.